and it was lowest in low-income and lower-middle-income countries. Ethics approval for study conduct was mandatory in 91% (n [ 106) of countries and regions, and 62% (n [ 66) were reported to have institutional committees. Challenges with obtaining timely approval for a study were reported in 53% (n [ 61) of regions but the challenges were similar across these regions. A potential limitation is the possibility of over-reporting or underreporting due to social desirability bias. This study highlights some of the major challenges for participating in and conducting kidney research and offers suggestions for improving global kidney research. C hronic kidney disease (CKD) is a global public health problem affecting as many as 10% of all populations. Projections of CKD prevalence show that the problem will continue to increase. [1] [2] [3] Among the several detrimental effects of CKD are the risk of progression to end-stage renal disease (ESRD), increased mortality risk due to cardiovascular disease and infections, 4 reduced quality of life, 5 and high cost of care. 6 Additional strategies including screening, diagnostics, and therapies through well-designed clinical research are needed to guide decision making and improve delivery of care. 7 Although the absolute number of publications in nephrology is increasing, 8, 9 the number and quality of randomized clinical trials (RCTs) in nephrology are unable to match the needs of a rising disease burden. [10] [11] [12] [13] One study assessing nephrology RCT quality and quantity highlighted major differences between nephrology and other specialties. 7 Increasing the output of high-quality studies in nephrology is therefore required to characterize the existing capacity, identify gaps, and provide opportunities for improving the care of CKD patients and bridging the gap between access to CKD care in low-versus high-income countries. 3 Information obtained from such studies could be utilized for policy making and advocacy to improve CKD care, especially in low-and lower-middle-income countries. The aim of this study, a part of the International Society (ISN) Global Kidney Health Atlas (GKHA) survey, was to conduct an on-the-spot assessment of capacity to conduct clinical research focusing on available infrastructure, funding, and workforce for research and the role of regulatory bodies.
Results
In total, 125 of 130 United Nations member states that received an invitation participated in the survey. Of these, 93% (n ¼ 116) responded to the questions relevant to participating in and conducting kidney research. The affiliations of survey respondents were nephrologists (85%), nonnephrology physicians (3%), health care administrators or policy makers (6%), and others affiliated with kidney disease patient advocacy (6%). 14 Capacity for clinical trial participation. Overall, there was low availability of institutionalized granting agencies. For instance, a national agency for funding of clinical trials was present in only (27%, n ¼ 31) of countries, with the lowest numbers reported for Africa (7%, n ¼ 2). There was a linear increase in capacity to participate in clinical trials by trial category: phase 1 (28%, n ¼ 33), phase 2 (40%, n ¼ 46), phase 3 (53%, n ¼ 61), and phase 4 (53%, n ¼ 62). In all the world regions, participation in clinical trials increased with increasing phase of the trial; only Africa had less than 50% participation in all phases of clinical trials. Also, only North America had 100% capacity to participate in all phases (1) (2) (3) (4) of clinical trials, while Western Europe had 100% participation in phase 2 to phase 4 clinical trials (Table 1) . When participation in clinical trials was assessed by income categories, low-income countries reported 18% (n ¼ 3) and 6% (n ¼ 1) capacity to participate in phase 1 and 2 trials, respectively, and no capacity to participate in phase 3 to phase 4 trials. By income category, participation in health services trials was found to be highest for low-income countries (76%, n ¼ 13), but was observed to be lowest for newly independent states (NIS) and Russia, South Asia, and Eastern and Central European regions ( Table 1) .
Availability of formal training for physicians and nonphysicians in conducting clinical trials. Only 46% (n ¼ 53) of countries had an established formal training program for physicians in conducting clinical trials. Formal training for physicians was unavailable in South Asia (0%) and was very low in Africa (27%, n ¼ 8) and the Middle East (15%, n ¼ 2). When the availability of formal training for physicians was ranked per income category, availability increased with increasing income level: low income (24%, n ¼ 4), lower-middle income (32%, n ¼ 10), upper-middle income (47%, n ¼ 14), and high income (66%, n ¼ 25) ( Table 1 ). Availability of training for nonphysicians in conducting clinical trials was slightly but generally lower than that for physicians and was also comparatively lower when countries were ranked by income level.
Availability of bio-banking facilities. Overall, 45% (n ¼ 52) of countries indicated that bio-banking facilities were available in their setting, with high-income countries reporting the highest number of countries with bio-banking facilities (79%, n ¼ 30). Both countries in the North American region had facilities for bio-banking, and most Western European countries (89%, n ¼ 8) reported availability of bio-banking facilities. Only 23% (n ¼ 7), 31% (n ¼ 5), 33% (n ¼ 2), and 38% (n ¼ 5) of countries in Africa, Latin America and the Caribbean, NIS and Russia, and the Middle East, respectively, had facilities for bio-banking (Table 1) .
Conducting, funding, and participating in observational cohort studies. Table 2 summarizes the responses obtained to questions on availability of trained workforce, resources, and involvement in observational studies in nondialysis, dialysis, and renal transplant patients. Most countries (85%, n ¼ 99) had personnel for participating in and conducting Table 3 provides a summary of responses obtained for the questions on the availability and type of ethics and drug regulatory authorities (regulatory bodies), challenges with obtaining approval from such committees, and proportion of sites with capacity for storage of clinical trial medications in different countries. It was observed that most countries (91%, n ¼ 106) require mandatory ethical clearance before studies can be performed. However, only high-income countries reported a 100% requirement for ethical clearance to carry out studies; the value for this was 82% (n ¼ 14), 84% (n ¼ 26), and 93% (n ¼ 28), respectively, for low-income, lower-middle-income, and upper-middleincome countries. Ethics approval was mostly obtained from institutional review committees, with few countries reporting regional committees. The challenges encountered in getting timely regulatory approval appeared to be similar in most countries. Overall, 20% (n ¼ 23) of countries reported that challenges were often present, and 25% (n ¼ 29) reported that challenges were occasionally present. In 52% (n ¼ 20) of high-income countries, "all sites" or "most sites" had capacity for storing clinical trial medications, compared with only 6% (n ¼ 1) in low-income countries, 23% (n ¼ 7) in lower-middle-income countries, and 30% (n ¼ 9) in upper-middle-income countries ( Table 3 ). In Africa (13%, n ¼ 4) and the Middle East (8%, n ¼ 1), there was a severe lack of capacity for storing clinical trial medications. Low-income countries also reported a higher percentage of sites (12%, n ¼ 2) with zero capacity for storage of clinical trial medications, compared with 3% (n ¼ 1) for high-income countries.
Discussion
Biomedical research capacity and productivity are known to vary widely; however, high-income countries in North America and Europe are regarded as leaders in biomedical research, [15] [16] [17] a reflection of their high gross domestic product, health care and research spending, and access to good quality research infrastructure. This GKHA survey is the first attempt, and the largest effort to date, by the international nephrology community to evaluate the readiness and capacity to conduct kidney research in all parts of the world. The results of this study have documented large gaps and differences across world regions to participate in and/or conduct kidney disease-related research. Specifically, this study highlights weaknesses in funding and a low capacity to take part in clinical trials for low-income and lower-middle-income countries (LMIC) (Supplementary Figure S1 ). 18 In some ISN regions, there was inadequate or complete absence of formal training of physicians to conduct clinical trials, lack of infrastructure (such as bio-banking facilities and facilities for the storage of trial medications) required to conduct studies, inadequate workforce, and large delays in obtaining regulatory approvals from regulatory authorities for conducting research. There is evidence that economic indicators such as gross domestic product correlate with scientific productivity. 17, [19] [20] [21] In India and Southeast Asia, poor funding from public and private sources was identified as a serious limitation to fostering a research culture, reduced interest in research, and a shift of focus to competing challenges such as provision of clinical care. 19 Lack of funding was suggested to have led to impoverished academic and laboratory facilities, worsened by weak institutional interest in encouraging research that meets international standards. 19 The same challenges regarding funding of universities and research institutions could also be responsible for low outputs in Africa and other LMIC regions. Using publication quality and outputs as a metric of research capacity, Winnik et al. 17 studied how the dissemination of cardiovascular research may be influenced by the wealth of a nation. After adjusting for markers of research quality and infrastructure, per capita gross domestic product remained a strong predictor for acceptance at congress (adjusted odds ratio [OR] for every 10,000 USD increase in per capita GDP, 1.44; 95% confidence interval [CI], 1.15-1.80), full-text publication within 5 years (adjusted OR, 1.49; 95% CI, 1.17 to 1.90), and high citation frequency (adjusted OR, 2.30; 95% CI 1.31-4.04). They concluded that investigators in less wealthy countries face challenges to disseminate their research, even after accounting for potential differences in the quality of their work and research infrastructure. 17 Further, this study indirectly gauged workforce availability for kidney research by assessing the availability of training for physicians and nonphysicians in conducting clinical trials. Although clinical trials involve patient care, the roles and responsibilities of members of the study team are unique and r e v i e w may differ from the usual day-to-day responsibilities in routine patient care. Such duties include awareness of and adherence to good clinical practice, data collection, sample collection and storage, drug storage, and accountability and reporting of events. Thus, in the face of an already low overall workforce for patient care, the workforce available for research may be even lower because adequate training has not been received. Participation in clinical trials and observational cohort studies of kidney disease was lowest for countries categorized as low-income. This is not surprising given that many of these countries already have challenges with availability of physical infrastructure and organizational structure for health service provision. [22] [23] [24] For instance, the availability of bio-banking facilities was found to be lowest in South Asia and Africa, while capacity for storing clinical trial medications was lowest for Africa and the Middle East. Although several countries reported availability of ethics and/or regulatory committees, there were significant hurdles to timely obtainment of regulatory approvals. This can significantly hinder participation in studies. Figure 1 shows data from www.clinicaltrials.gov 18 on participation in CKD trials around the world, with low participation in developing world regions.
There are no generic solutions to the identified challenges and barriers to research. However, concerted effort is required to address these problems. Over the years, the ISN has developed a set of core programs designed to enable nephrologists, especially in low-income countries to access highly valued education and training grants. 25 Understandably, due to the need to improve clinical training and kidney care delivery in developing countries, 5 of the 6 core programs are primarily focused on clinical training (Fellowship Program, Sister Renal Centres Program, Sister Transplant Centre Program, CME Program, and Educational Ambassadors Program); the other program is focused on research support (Clinical Research Program [CRP]) and provides grants for research projects in LMIC settings (http://www. theisn.org/programs). However, it is expected that individual and institutional beneficiaries of the programs that focus on clinical training will also develop their research skills as a byproduct. The ISN has provided significant support to researchers from LMICs for projects in their countries. 25 The ISN-CRP has recently started a training course for manuscript and grant writing in LMICs, and offering other types of research training, especially on study design or clinical trials, would be helpful. To maximize the scale and quality of funded projects, opportunities for partnership funding should be sought. The ISN-CRP also has a broader educational role, for example through webinars and other educational material via the online ISN Academy. Several of these have focused on research capacity and methodology. Other ISN programs such as the ISN-ACT (Advancing Clinical Trials) (http://www. theisn.org/research/isn-act) and iNET-CKD (the International Network of Chronic Kidney Disease cohort studies, https://www.theisn.org/research/inet-ckd) aim to increase the number of international high-quality clinical trials and cohort studies in nephrology, provide networking opportunities, and grow the capacity of the global nephrology community, particularly in countries and regions where clinical trials participation is low or does not take place.
A potential limitation of this study is the possibility of over-or under-reporting due to social desirability bias. However, responses were checked for validity against the response provided by regional leaders to reduce the risk of such biases.
In conclusion, this study, which is the first global effort to assess capacity for kidney research in all countries and world regions, has identified gaps that limit research capacity across the world including inadequate funding, limited workforce, low level of available infrastructure, and issues related to delays in getting regulatory approval to conduct research. There is a need to coordinate efforts, leveraging already established programs to improve research capacity across the world.
Methods
This study was based on data obtained from all the regions of the world through an online survey carried out by the ISN in 2016. The detailed methodology utilized in the GKHA project has been described in detail elsewhere. 14, 26 In brief, the GKHA project was a multinational, cross-sectional survey conducted by the ISN to assess current capacity for kidney care across the world. The survey was conducted in states and territories recognized by the United Nations, focusing on the 130 countries represented by the ISN's 10 regional boards (Africa, East and Central Europe, Latin America, Middle East, North America, North and East Asia, Oceania and Southeast Asia, NIS and Russia, South Asia, and Western Europe). For the purpose of analysis, countries were grouped by 2014 World Bank country classification as low-, lower-middle-, upper-middle-, and high-income nations 27 and ISN region. 28 The GKHA survey covered 2 broad sections: (i) assessment of capacity and response to CKD and acute kidney injury premised on 6 health system building blocks and (ii) response of the nephrology community to strategies and policy framework formulation as well as capacity for research and development. This study focused specifically on capacity for research and development. The questions were aimed to determine: (i) available funding to conduct clinical trials; (ii) participation in kidney disease clinical trials; (iii) formal training of staff (physicians and nonphysicians) to conduct clinical trials; (iv) availability of facilities for biobanking; (v) availability of workforce and funding for observational cohort studies in kidney disease; (vi) availability, accessibility, and challenges in getting timely regulatory approvals for studies; and (vii) capacity for storing clinical trial medications. The data are presented as frequencies and percentages.
